Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: A pooled analysis of the intandem 1 and 2 studies

Anne L. Peters, Darren K. McGuire, Thomas Danne, Jake A. Kushner, Helena W. Rodbard, Ketan Dhatariya, Sangeeta Sawhney, Phillip Banks, Wenjun Jiang, Michael J. Davies, Pablo Lapuerta

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

OBJECTIVE To evaluate the incidence and risk factors for diabetic ketoacidosis (DKA) and related adverse events (AEs) in adults with type 1 diabetes treated with sotagliflozin adjunctive to insulin. RESEARCH DESIGN AND METHODS Data from two identically designed, 52-week, randomized studies were pooled and analyzed for DKA, changes in b-hydroxybutyrate (BHB), and percentage of patients with BHB >0.6 and >1.5 mmol/L. The patients were administered placebo, sotagliflozin 200 mg, or sotagliflozin 400 mg once daily. RESULTS A total of 191 ketosis-related AEs were reported, and 98 underwent adjudication. Of these, 37 events (36 patients) were adjudicated as DKA, with an exposure-adjusted incidence rate of 0.2, 3.1, and 4.2 events per 100 patient-years for placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively. No patient died of a DKA event. From a baseline BHB of ∼0.13 mmol/L, sotagliflozin treatment led to a small median increase over 52 weeks (£0.05 mmol/L at all time points). Of sotagliflozin-treated patients, approximately 47% and 7% had ‡1 BHB measurement >0.6 mmol/ L and >1.5 mmol/L, respectively (vs. 20% and 2%, respectively, of placebo-treated patients). Subsequent to the implementation of a risk mitigation plan, annualized DKA incidence was lower versus preimplementation in both the sotagliflozin 200 and 400 mg groups. CONCLUSIONS In patients with type 1 diabetes, confirmed DKA incidence increased when sotagliflozin was added to insulin compared with insulin alone. A lower incidence of DKA was observed following the implementation of an enhanced risk mitigation plan, suggest-ing that this risk can be managed with patient education.

Original languageEnglish (US)
Pages (from-to)2713-2720
Number of pages8
JournalDiabetes care
Volume43
Issue number11
DOIs
StatePublished - 2020

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Diabetic ketoacidosis and related events with sotagliflozin added to insulin in adults with type 1 diabetes: A pooled analysis of the intandem 1 and 2 studies'. Together they form a unique fingerprint.

Cite this